Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-08-15. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 31.7% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerhepatitiscellsvaccinedisease
  Phrases that lowered it: participantparticipantsaminotransferasesorafenibtrial
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 28.0% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 84.7% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 19 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 139 (lowers risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) NCT02702414 · started 2016 · scored riskier than 39% of active trials completed
• Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) NCT02702401 · started 2016 · scored riskier than 53% of active trials completed
• Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy NCT05101629 · started 2022 · scored riskier than 50% of active trials completed
• Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors NCT04696055 · started 2021 · scored riskier than 48% of active trials completed
• Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib NCT03163992 · started 2017 · scored riskier than 41% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.